REFERENCES
2. GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5:e594-610.
3. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78:1463-71.
4. Jin J, Cai X, Rao P, Xu J, Li J. Microbiota and immune dynamics in rheumatoid arthritis: Mechanisms and therapeutic potential. Best Pract Res Clin Rheumatol. 2025;39:102035.
5. Catrina AI, Deane KD, Scher JU. Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis. Rheumatology. 2016;55:391-402.
6. Boutet MA, Courties G, Nerviani A, et al. Novel insights into macrophage diversity in rheumatoid arthritis synovium. Autoimmun Rev. 2021;20:102758.
7. Konzett V, Aletaha D. Management strategies in rheumatoid arthritis. Nat Rev Rheumatol. 2024;20:760-9.
8. Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16:316-33.
9. Guo D, Liu H, Zhao S, et al. Synergistic rheumatoid arthritis therapy by interrupting the detrimental feedback loop to orchestrate hypoxia M1 macrophage polarization using an enzyme-catalyzed nanoplatform. Bioact Mater. 2024;41:221-38.
10. Hanlon MM, Smith CM, Canavan M, et al. Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset. Sci Adv. 2024;10:eadj1252.
11. Wang Y, Shi P, Chen Q, et al. Mitochondrial ROS promote macrophage pyroptosis by inducing GSDMD oxidation. J Mol Cell Biol. 2019;11:1069-82.
12. Ding Z, Liu S, Wang X, et al. LOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis. Cardiovasc Res. 2014;103:619-28.
13. Komatsu N, Takayanagi H. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat Rev Rheumatol. 2022;18:415-29.
14. Prasad P, Verma S, Surbhi, Ganguly NK, Chaturvedi V, Mittal SA. Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem. 2023;478:69-88.
15. Jung SM, Han M, Kim EH, Jung I, Park YB. Comparison of developing tuberculosis following tumor necrosis factor inhibition and interleukin-6 inhibition in patients with rheumatoid arthritis: a nationwide observational study in South Korea, 2013-2018. Arthritis Res Ther. 2022;24:157.
16. Biesemann N, Margerie D, Asbrand C, et al. Additive efficacy of a bispecific anti-TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis. Sci Transl Med. 2023;15:eabq4419.
17. Lauper K, Kearsley-Fleet L, Galloway JB, Watson KD, Hyrich KL, Lunt M; BSRBR-RA Contributors Group. Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter? Rheumatology 2024;63:1957-64.
18. Zhang R, Lin X, Lin R, et al. Effectively alleviate rheumatoid arthritis via maintaining redox balance, inducing macrophage repolarization and restoring homeostasis of fibroblast-like synoviocytes by metformin-derived carbon dots. J Nanobiotechnology. 2025;23:58.
19. Zhang X, Fu X, Chen W, et al. Amelioration of the rheumatoid arthritis microenvironment using celastrol-loaded silver-modified ceria nanoparticles for enhanced treatment. J Nanobiotechnology. 2025;23:372.
20. Zhang Y, Mao X, Li W, et al. Tripterygium wilfordii: an inspiring resource for rheumatoid arthritis treatment. Med Res Rev. 2021;41:1337-74.
21. Tong L, Zhao Q, Datan E, et al. Triptolide: reflections on two decades of research and prospects for the future. Nat Prod Rep. 2021;38:843-60.
22. Sarasati A, Syahruddin MH, Nuryanti A, et al. Plant-derived exosome-like nanoparticles for biomedical applications and regenerative therapy. Biomedicines. 2023;11:1053.
23. Bai C, Liu J, Zhang X, et al. Research status and challenges of plant-derived exosome-like nanoparticles. Biomed Pharmacother. 2024;174:116543.
24. Yi Q, Xu Z, Thakur A, et al. Current understanding of plant-derived exosome-like nanoparticles in regulating the inflammatory response and immune system microenvironment. Pharmacol Res. 2023;190:106733.
25. Lin Y, Yi O, Hu M, et al. Multifunctional nanoparticles of sinomenine hydrochloride for treat-to-target therapy of rheumatoid arthritis via modulation of proinflammatory cytokines. J Control Release. 2022;348:42-56.
26. Zheng BY, Wang XJ, Wen HS, et al. Exosomes-mediated molecular mechanisms underlying the transformation of ovarian tissue into a functional placental analogue in black rockfish (Sebastes schlegelii). Zool Res. 2026;47:1661-77.
27. Li P, Yang X, Yang Y, et al. Synergistic effect of all-trans-retinal and triptolide encapsulated in an inflammation-targeted nanoparticle on collagen-induced arthritis in mice. J Control Release. 2020;319:87-103.
29. Yang Y, Guo L, Wang Z, et al. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and Re-polarization. Biomaterials. 2021;264:120390.
30. Ruffell B, Poon GF, Lee SS, et al. Differential use of chondroitin sulfate to regulate hyaluronan binding by receptor CD44 in inflammatory and interleukin 4-activated macrophages. J Biol Chem. 2011;286:19179-90.
31. Rios de la Rosa JM, Tirella A, Gennari A, Stratford IJ, Tirelli N. The CD44-mediated uptake of hyaluronic acid-based carriers in macrophages. Adv Healthc Mater. 2017;6:1601012.
32. Walvekar P, Lulinski P, Kumar P, Aminabhavi TM, Choonara YE. A review of hyaluronic acid-based therapeutics for the treatment and management of arthritis. Int J Biol Macromol. 2024;264:130645.
33. Yang X, Li J, Xu C, Zhang G, Che X, Yang J. Potential mechanisms of rheumatoid arthritis therapy: Focus on macrophage polarization. Int Immunopharmacol. 2024;142:113058.
34. Fang WY, Tseng YT, Lee TY, et al. Triptolide prevents LPS-induced skeletal muscle atrophy via inhibiting NF-κB/TNF-α and regulating protein synthesis/degradation pathway. Br J Pharmacol. 2021;178:2998-3016.
35. Lv C, Cheng T, Zhang B, Sun K, Lu K. Triptolide protects against podocyte injury in diabetic nephropathy by activating the Nrf2/HO-1 pathway and inhibiting the NLRP3 inflammasome pathway. Ren Fail. 2023;45:2165103.
36. Udagawa N, Koide M, Nakamura M, et al. Osteoclast differentiation by RANKL and OPG signaling pathways. J Bone Miner Metab. 2021;39:19-26.
37. Wu YZ, Chen WY, Zeng Y, et al. Inflammation-responsive mesoporous Silica nanoparticles with synergistic anti-inflammatory and joint protection effects for rheumatoid arthritis treatment. Pharm Res. 2024;41:1493-505.
38. Priya S, Verma V, Roy A, Singhvi G. Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-β-boswellic acid in rheumatoid arthritis treatment. J Nanobiotechnology. 2025;23:725.
39. Qadri MM. Targeting CD44 receptor pathways in degenerative joint diseases: involvement of proteoglycan-4 (PRG4). Pharmaceuticals. 2023;16:1425.
40. Cui D, Xu D, Yue S, et al. Recent advances in the pharmacological applications and liver toxicity of triptolide. Chem Biol Interact. 2023;382:110651.
41. Zhang C, Weng Y, Wang H, et al. A synergistic effect of triptolide and curcumin on rheumatoid arthritis by improving cell proliferation and inducing cell apoptosis via inhibition of the IL-17/NF-κB signaling pathway. Int Immunopharmacol. 2024;142:112953.
42. Gouze JN, Gouze E, Popp MP, et al. Exogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther. 2006;8:R173.
43. Stoppoloni D, Politi L, Leopizzi M, et al. Effect of glucosamine and its peptidyl-derivative on the production of extracellular matrix components by human primary chondrocytes. Osteoarthritis Cartilage. 2015;23:103-13.
44. Wang P, Zhang Y, Lei H, et al. Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis. Carbohydr Polym. 2023;316:121018.
46. Jin K, Luo Z, Zhang B, Pang Z. Biomimetic nanoparticles for inflammation targeting. Acta Pharm Sin B. 2018;8:23-33.
47. Rahman M, Beg S, Anwar F, et al. Liposome-based nanomedicine therapeutics for rheumatoid arthritis. Crit Rev Ther Drug Carrier Syst. 2017;34:283-316.
48. Han Z, Gao X, Wang Y, et al. Ultrasmall iron-quercetin metal natural product nanocomplex with antioxidant and macrophage regulation in rheumatoid arthritis. Acta Pharm Sin B. 2023;13:1726-39.
49. Buttari B, Recalchi S, Riitano G, et al. Extracellular microvesicles from patients with Rheumatoid arthritis promote dendritic cell activation in vitro. Front Immunol. 2025;16:1532114.
50. Riitano G, Recalchi S, Capozzi A, et al. The role of autophagy as a trigger of post-translational modifications of proteins and extracellular vesicles in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2023;24:12764.
